Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The […]readmore
Tags : Novel
Shots: Zymeworks to get $5M upfront plus research funding payments from LEO, $231M as milestone to commercialize first candidate & up to $244M for the second candidate along with 20% […]readmore
Shots: The NDA and MAA Acceptance of Siponimod is based on P-III EXPAND study, assessing Siponimod vs PBO in adults with Secondary Progression Multiple Sclerosis (SPMS) evaluating its safety and […]readmore
Shots: Sanofi and Evotec launches BRIDGE LAB031, designed to convert academic research into drug discovery candidates for multiple therapeutic areas. BRIDGE is a public-private partnership combining academia, biotech and venture […]readmore
Shots: EU approval is based on results of APOLLO P-III study involving 19 countries in ratio (2:1) assessing Onpattro vs PBO once q3w for 18mos showing safety and efficacy Onpattro […]readmore
Shots: Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further […]readmore